TREACE MEDICAL CONCEPTS INC
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
On December 16, 2024, Sean F. Scanlan, the Company's Chief Innovation Officer, adopted a Rule 10b5-1 trading plan. Mr. Scanlan's trading plan provides for the exercise and sale of 50,000 shares of the Company's common stock subject to stock options, until March 13, 2026. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, and the Company's policies regarding transactions in the Company's securities.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.